The Droplex KRAS Mutation Test is an in vitro molecular diagnostic test that detects individual mutations in the KRAS gene for colorectal cancer (CRC) patients . As with the lung cancer companion diagnostic test, DNA extracted from the patient's cancer tissue or plasma is analyzed to determine the presence of each mutation and the Mutation Index is measured. The test results are used to select patients who need targeted anticancer drugs such as Cetuximab or Panitumumab or other treatments depending on the presence or absence of each mutation. Mutations of KRAS gene Codons 12, 13, 59, 61, 117, 146 in DNA derived from colorectal cancer (CRC) patient tissue after formalin fixation were paraffin-embedded (FFPET) by the droplet digital polymerase chain reaction method.
Colorectal Cancer, Non Small Cell Lung Cancer, Pancreatic Cancer
KRAS (KRAS proto-oncogene GTPase)
Erbitux (cetuximab), Vectibix (panitumumab)